Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer
David Cunningham, William Allum, Sally Patricia Stenning, Jeremy N. Thompson, Cornelis J.�H. van de Velde, Marianne C. Nicolson, J. Howard Scarffe, Fiona J. Lofts, Stephen J. Falk, Timothy J. Iveson, David B. Smith, Ruth Elizabeth Langley, Monica Verma, Simon Weeden, Yu Jo Chua
New England Journal of Medicine · 2006 · 6,411 citations
No retraction on record in OpenAlex.Check Crossref now
Cite this paper
Cunningham, D., Allum, W., Stenning, S. P., Thompson, J. N., Velde, C. J. van de, Nicolson, M. C., Scarffe, J. H., Lofts, F. J., Falk, S. J., Iveson, T. J., Smith, D. B., Langley, R. E., Verma, M., Weeden, S., & Chua, Y. J. (2006). Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. New England Journal of Medicine, 355(1), 11–20. https://doi.org/10.1056/nejmoa055531
In text: (Cunningham et al., 2006)
Ask a question about this research
One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.
Abstract
BACKGROUND: A regimen of epirubicin, cisplatin, and infused fluorouracil (ECF) improves survival among patients with incurable locally advanced or metastatic gastric adenocarcinoma. We assessed whether the addition of a perioperative regimen of ECF to surgery improves outcomes among patients with potentially curable gastric cancer. METHODS: We randomly assigned patients with resectable adenocarcinoma of the stomach, esophagogastric junction, or lower esophagus to either perioperative chemotherapy and surgery (250 patients) or surgery alone (253 patients). Chemotherapy consisted of three preoperative and three postoperative cycles of intravenous epirubicin (50 mg per square meter of body-surface area) and cisplatin (60 mg per square meter) on day 1, and a continuous intravenous infusion of fluorouracil (200 mg per square meter per day) for 21 days. The primary end point was overall survival. RESULTS: ECF-related adverse effects were similar to those previously reported among patients with advanced gastric cancer. Rates of postoperative complications were similar in the perioperative-chemotherapy group and the surgery group (46 percent and 45 percent, respectively), as were the numbers of deaths within 30 days after surgery. The resected tumors were significantly smaller and less advanced in the perioperative-chemotherapy group. With a median follow-up of four years, 149 patients in the perioperative-chemotherapy group and 170 in the surgery group had died. As compared with the surgery group, the perioperative-chemotherapy group had a higher likelihood of overall survival (hazard ratio for death, 0.75; 95 percent confidence interval, 0.60 to 0.93; P=0.009; five-year survival rate, 36 percent vs. 23 percent) and of progression-free survival (hazard ratio for progression, 0.66; 95 percent confidence interval, 0.53 to 0.81; P<0.001). CONCLUSIONS: In patients with operable gastric or lower esophageal adenocarcinomas, a perioperative regimen of ECF decreased tumor size and stage and significantly improved progression-free and overall survival. (Current Controlled Trials number, ISRCTN93793971 [controlled-trials.com].).
Related papers
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene1987
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER22001
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer1989
- Comprehensive molecular characterization of gastric adenocarcinoma2014
- Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer2012
Metadata from OpenAlex (CC0). Citations are generated from the published record.